Phosphodiesterase type 5 inhibitor use among pregnant and reproductive‐age women in the United States.

MLA

Liu, Wei, et al. “Phosphodiesterase Type 5 Inhibitor Use among Pregnant and Reproductive‐age Women in the United States.” Pharmacoepidemiology & Drug Safety, vol. 30, no. 2, Feb. 2021, pp. 126–34. EBSCOhost, https://doi.org/10.1002/pds.5112.

APA

Liu, W., Menzin, T. J., Woods, C. M., Haug, N. R., Li, J., Mathew, J. A., Nguyen, C. P., Chai, G. P., Moeny, D. G., & Shinde, M. (2021). Phosphodiesterase type 5 inhibitor use among pregnant and reproductive‐age women in the United States. Pharmacoepidemiology & Drug Safety, 30(2), 126–134. https://doi.org/10.1002/pds.5112

Chicago

Liu, Wei, Talia J. Menzin, Corinne M. Woods, Nicole R. Haug, Jie Li, Justin A. Mathew, Christine P. Nguyen, Grace P. Chai, David G. Moeny, and Mayura Shinde. 2021. “Phosphodiesterase Type 5 Inhibitor Use among Pregnant and Reproductive‐age Women in the United States.” Pharmacoepidemiology & Drug Safety 30 (2): 126–34. doi:10.1002/pds.5112.